Compare Oscar Health Inc (OSCR) vs Tempus AI (TEM) Price & Performance

Oscar Health (OSCR) trades at $29.60, up 1.72% with mixed technical signals showing neutral overall momentum. The company reported strong Q1 2026 earnings beat but faces profitability challenges with negative margins. Revenue growth from $11.7B in 2025 to projected $13.3B in 2026 indicates expansion, while cash flow trends show operational improvement. Analyst consensus is divided with 27% buy ratings against a $24.67 price target below current levels.

The stock presents growth potential through revenue expansion and cash flow generation, but profitability concerns and negative ROE pose significant risks. Current valuation at 0.61 P/S suggests reasonable pricing for growth, though execution on margin improvement remains critical for sustained upside.

Tempus AI (TEM) trades at $48.41, down 7.74% amid market reaction to its $1.5 billion acquisition of Personalis. The stock shows bearish technical signals with negative moving averages and oversold RSI levels. Fundamentally, the company maintains strong revenue growth ($1.27B in 2025) but faces significant losses (-$245M net income) and negative margins. Recent news highlights strategic expansion in cancer diagnostics through AI-driven platforms.

Despite analyst optimism (61.5% buy ratings, $68.50 target), TEM faces execution risks from the major acquisition and persistent profitability challenges. The stock's current discount to target offers potential upside if integration succeeds, but high cash burn and competitive pressures require careful monitoring for investors considering entry at these levels.